GeneNews Limited

GeneNews Limited

November 09, 2011 08:30 ET

GeneNews Diagnostics Launches ColonSentry in Malaysia

TORONTO, ONTARIO--(Marketwire - Nov. 9, 2011) - GeneNews Limited (TSX:GEN), a molecular diagnostics company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced the commercial launch of ColonSentry™, the world's first blood-based test to determine a person's current risk for colorectal cancer, in Malaysia through GeneNews Diagnostics Sdn. Bhd. The formal launch ceremony was officiated by Y'B Senator Tan Sri Dr. Koh Tsu Koon, a Minister in the Malaysian Prime Minister's Department.

"We are excited that GeneNews Diagnostics will now be able to provide the Malaysian population with access to this potentially life-saving colorectal cancer pre-screening tool. We also believe that commercial success in Malaysia, a key country in the Southeast Asian market, will help facilitate the commercial expansion of the ColonSentry test throughout this part of the world", said Gailina J. Liew, President and Chief Operating Officer of GeneNews.

About GeneNews Diagnostics Sdn. Bhd.

GeneNews Diagnostics is a privately-held Malaysian company that will work with GeneNews Limited to commercialize ColonSentry in Malaysia and Southeast Asia. GeneNews Diagnostics was granted BioNexus Status by the Malaysian Biotechnology Corporation Sdn. Bhd. in December 2009 and is the recipient of a seed capital grant for commercialization purposes.

About GeneNews

GeneNews is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease-specific biomarkers. The Company has a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews' lead product, ColonSentry, is the world's first blood test for colorectal cancer. For more information on GeneNews and ColonSentry™, visit or

Forward-Looking Statements

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

Contact Information